Atorvastatin Drug Interactions
157Total Interactions
45Severe
58Moderate
3Mild
| Drug | Severity | Summary |
|---|---|---|
| Acipimox | SEVERE | Acipimox is predicted to increase the risk of rhabdomyolysis when given with Atorvastatin. Manufa... |
| Alcohol | SEVERE | Alcohol -induced liver disease increases the risk of hepatotoxicity in those taking Atorvastatin.... |
| Aprepitant | SEVERE | Aprepitant is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor an... |
| Atazanavir | SEVERE | Atazanavir is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or a... |
| Bemiparin | SEVERE | Atorvastatin might increase the risk of hepatotoxicity when given with Bemiparin (high-dose). Man... |
| Bezafibrate | SEVERE | Bezafibrate increases the risk of rhabdomyolysis when given with Atorvastatin. Manufacturer advis... |
| Ceritinib | SEVERE | Ceritinib is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or ad... |
| Ciclosporin | SEVERE | Ciclosporin markedly to very markedly increases the exposure to Atorvastatin. Manufacturer advise... |
| Ciprofibrate | SEVERE | Ciprofibrate increases the risk of rhabdomyolysis when given with Atorvastatin. Manufacturer advi... |
| Clarithromycin | SEVERE | Clarithromycin is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid ... |
| Cobicistat | SEVERE | Cobicistat is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or a... |
| Colchicine | SEVERE | Colchicine has been reported to cause rhabdomyolysis when given with Atorvastatin. Manufacturer a... |
| Dalteparin | SEVERE | Atorvastatin might increase the risk of hepatotoxicity when given with Dalteparin (high-dose). Ma... |
| Daptomycin | SEVERE | Atorvastatin is predicted to increase the risk of rhabdomyolysis when given with Daptomycin. Manu... |
| Darolutamide | SEVERE | Darolutamide is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid. |
| Darunavir | SEVERE | Darunavir is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or ad... |
| Diltiazem | SEVERE | Diltiazem slightly increases the exposure to Atorvastatin. Manufacturer advises monitor and adjus... |
| Dronedarone | SEVERE | Dronedarone slightly increases the exposure to Atorvastatin. Manufacturer advises monitor and adj... |
| Elafibranor | SEVERE | Elafibranor might increase the risk of muscle effects when given with Atorvastatin. Manufacturer ... |
| Enoxaparin | SEVERE | Atorvastatin might increase the risk of hepatotoxicity when given with Enoxaparin (high-dose). Ma... |
| Erythromycin | SEVERE | Erythromycin slightly increases the exposure to Atorvastatin. Manufacturer advises monitor and ad... |
| Fenofibrate | SEVERE | Fenofibrate increases the risk of rhabdomyolysis when given with Atorvastatin. Manufacturer advis... |
| Fluconazole | SEVERE | Fluconazole is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor a... |
| Fosamprenavir | SEVERE | Fosamprenavir is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid o... |
| Fostemsavir | SEVERE | Fostemsavir is predicted to increase the exposure to Atorvastatin. Manufacturer advises adjust st... |
| Fusidate | SEVERE | Fusidate has been reported to cause rhabdomyolysis when given with Atorvastatin. Manufacturer adv... |
| Gemfibrozil | SEVERE | Gemfibrozil causes a small increase in the exposure to Atorvastatin. Manufacturer advises avoid. |
| Glecaprevir | SEVERE | Glecaprevir with pibrentasvir markedly increases the exposure to Atorvastatin. Manufacturer advis... |
| Idelalisib | SEVERE | Idelalisib is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or a... |
| Imatinib | SEVERE | Imatinib is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor and ... |
| Itraconazole | SEVERE | Itraconazole is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or... |
| Ketoconazole | SEVERE | Ketoconazole is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or... |
| Letermovir | SEVERE | Letermovir moderately increases the exposure to Atorvastatin. Manufacturer advises avoid or adjus... |
| Lopinavir | SEVERE | Lopinavir is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or ad... |
| Netupitant | SEVERE | Netupitant is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor an... |
| Nicotinic acid | SEVERE | Nicotinic acid might increase the risk of rhabdomyolysis when given with Atorvastatin. Manufactur... |
| Nirmatrelvir | SEVERE | Nirmatrelvir boosted with ritonavir is predicted to increase the concentration of Atorvastatin. M... |
| Pibrentasvir | SEVERE | Pibrentasvir with glecaprevir markedly increases the exposure to Atorvastatin. Manufacturer advis... |
| Posaconazole | SEVERE | Posaconazole is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or... |
| Ritonavir | SEVERE | Ritonavir is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or ad... |
| Tinzaparin | SEVERE | Atorvastatin might increase the risk of hepatotoxicity when given with Tinzaparin (high-dose). Ma... |
| Tucatinib | SEVERE | Tucatinib is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or ad... |
| Velpatasvir | SEVERE | Velpatasvir with sofosbuvir slightly increases the exposure to Atorvastatin. Manufacturer makes n... |
| Verapamil | SEVERE | Verapamil is predicted to slightly to moderately increase the exposure to Atorvastatin. Manufactu... |
| Voriconazole | SEVERE | Voriconazole is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or... |
| Aliskiren | MODERATE | Atorvastatin slightly to moderately increases the exposure to Aliskiren. Manufacturer makes no re... |
| Amiodarone | MODERATE | Amiodarone is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor an... |
| Apalutamide | MODERATE | Apalutamide is predicted to decrease the exposure to Atorvastatin. Manufacturer advises monitor. |
| Belumosudil | MODERATE | Belumosudil is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or ... |
| Bosentan | MODERATE | Bosentan is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommendat... |
| Bulevirtide | MODERATE | Bulevirtide is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid or ... |
| Cabazitaxel | MODERATE | Cabazitaxel is predicted to affect the exposure to Atorvastatin. Manufacturer advises take 12 hou... |
| Carbamazepine | MODERATE | Carbamazepine is predicted to decrease the exposure to Atorvastatin. Manufacturer advises monitor... |
| Ceftobiprole | MODERATE | Ceftobiprole is predicted to increase the concentration of Atorvastatin. Manufacturer makes no re... |
| Cenobamate | MODERATE | Cenobamate is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommend... |
| Cilostazol | MODERATE | Cilostazol is predicted to increase the exposure to Atorvastatin. Manufacturer advises caution. |
| Crizotinib | MODERATE | Crizotinib is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor an... |
| Dabrafenib | MODERATE | Dabrafenib is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommend... |
| Danicopan | MODERATE | Danicopan is predicted to increase the exposure to Atorvastatin. Manufacturer advises caution. |
| Efavirenz | MODERATE | Efavirenz is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommenda... |
| Elbasvir | MODERATE | Elbasvir with grazoprevir slightly increases the exposure to Atorvastatin. Manufacturer advises a... |
| Elexacaftor | MODERATE | Elexacaftor is predicted to increase the exposure to Atorvastatin. Manufacturer advises caution. |
| Eltrombopag | MODERATE | Eltrombopag is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor a... |
| Empagliflozin | MODERATE | Empagliflozin has been reported to increase the risk of muscle effects when given after Atorvasta... |
| Enzalutamide | MODERATE | Enzalutamide is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recomme... |
| Eslicarbazepine | MODERATE | Eslicarbazepine is predicted to decrease the exposure to Atorvastatin. Manufacturer advises monit... |
| Etravirine | MODERATE | Etravirine is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommend... |
| Fosphenytoin | MODERATE | Fosphenytoin is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recomme... |
| Fostamatinib | MODERATE | Fostamatinib is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor ... |
| Grazoprevir | MODERATE | Grazoprevir moderately increases the exposure to Atorvastatin. Manufacturer advises adjust Atorva... |
| Isavuconazole | MODERATE | Isavuconazole slightly increases the exposure to Atorvastatin. Manufacturer advises monitor adver... |
| Ledipasvir | MODERATE | Ledipasvir with sofosbuvir is predicted to increase the exposure to Atorvastatin. Manufacturer ad... |
| Leflunomide | MODERATE | Leflunomide is predicted to increase the exposure to Atorvastatin. Manufacturer advises caution. |
| Leniolisib | MODERATE | Leniolisib is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid. |
| Lorlatinib | MODERATE | Lorlatinib is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommend... |
| Miconazole | MODERATE | Miconazole (including the oral gel) might increase the exposure to Atorvastatin. Manufacturer mak... |
| Mitotane | MODERATE | Mitotane is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommendat... |
| Nevirapine | MODERATE | Nevirapine is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommend... |
| Nilotinib | MODERATE | Nilotinib is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor and... |
| Olaparib | MODERATE | Olaparib is predicted to increase the exposure to Atorvastatin. Manufacturer advises caution. |
| Oxcarbazepine | MODERATE | Oxcarbazepine is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recomm... |
| Pazopanib | MODERATE | Pazopanib might affect the exposure to Atorvastatin. Manufacturer advises caution. |
| Phenobarbital | MODERATE | Phenobarbital is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recomm... |
| Phenytoin | MODERATE | Phenytoin moderately decreases the exposure to Atorvastatin. Manufacturer makes no recommendation. |
| Pirtobrutinib | MODERATE | Pirtobrutinib is predicted to increase the exposure to Atorvastatin. Manufacturer advises caution. |
| Primidone | MODERATE | Primidone is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommenda... |
| Ranolazine | MODERATE | Ranolazine is predicted to increase the exposure to Atorvastatin. Manufacturer makes no recommend... |
| Regorafenib | MODERATE | Regorafenib is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor a... |
| Rifampicin | MODERATE | Rifampicin markedly decreases the exposure to Atorvastatin. Manufacturer advises take both drugs ... |
| Roxadustat | MODERATE | Roxadustat is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor ad... |
| Sacubitril | MODERATE | Sacubitril with valsartan increases the exposure to Atorvastatin. Manufacturer advises caution. |
| Sarilumab | MODERATE | Sarilumab is predicted to decrease the exposure to Atorvastatin. Manufacturer advises caution. |
| Sotorasib | MODERATE | Sotorasib is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recommenda... |
| Sparsentan | MODERATE | Sparsentan is predicted to increase the exposure to Atorvastatin. Manufacturer makes no recommend... |
| St John's wort | MODERATE | St John's wort is predicted to decrease the exposure to Atorvastatin. Manufacturer makes no recom... |
| Talazoparib | MODERATE | Atorvastatin very slightly increases the exposure to Talazoparib. Manufacturer makes no recommend... |
| Tedizolid | MODERATE | Tedizolid is predicted to increase the exposure to Atorvastatin. Manufacturer advises avoid. |
| Teriflunomide | MODERATE | Teriflunomide is predicted to increase the exposure to Atorvastatin. Manufacturer advises caution. |
| Tocilizumab | MODERATE | Tocilizumab is predicted to decrease the exposure to Atorvastatin. Manufacturer advises monitor a... |
| Vadadustat | MODERATE | Vadadustat is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor an... |
| Venetoclax | MODERATE | Venetoclax is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor. |
| Voclosporin | MODERATE | Voclosporin is predicted to increase the concentration of Atorvastatin. Manufacturer advises moni... |
| Voxilaprevir | MODERATE | Voxilaprevir with sofosbuvir and velpatasvir is predicted to increase the exposure to Atorvastati... |
| Encorafenib | MILD | Encorafenib is predicted to increase the exposure to Atorvastatin. Manufacturer advises caution. |
| Grapefruit | MILD | Grapefruit juice increases the exposure to Atorvastatin. Manufacturer advises caution. |
| Lomitapide | MILD | Lomitapide increases the exposure to Atorvastatin. Manufacturer advises adjust Lomitapide dose or... |
| Acitretin | LOW | Both Atorvastatin and Acitretin can increase the risk of hepatotoxicity. |
| Alectinib | LOW | Both Atorvastatin and Alectinib can increase the risk of hepatotoxicity. |
| Anidulafungin | LOW | Both Atorvastatin and Anidulafungin can increase the risk of hepatotoxicity. |
| Asparaginase | LOW | Both Atorvastatin and Asparaginase can increase the risk of hepatotoxicity. |
| Bexarotene | LOW | Both Atorvastatin and Bexarotene can increase the risk of hepatotoxicity. |
| Capecitabine | LOW | Both Atorvastatin and Capecitabine can increase the risk of hepatotoxicity. |
| Carmustine | LOW | Both Atorvastatin and Carmustine can increase the risk of hepatotoxicity. |
| Caspofungin | LOW | Both Atorvastatin and Caspofungin can increase the risk of hepatotoxicity. |
| Clofarabine | LOW | Both Atorvastatin and Clofarabine can increase the risk of hepatotoxicity. |
| Crisantaspase | LOW | Both Atorvastatin and Crisantaspase can increase the risk of hepatotoxicity. |
| Cytarabine | LOW | Both Atorvastatin and Cytarabine can increase the risk of hepatotoxicity. |
| Dactinomycin | LOW | Both Atorvastatin and Dactinomycin can increase the risk of hepatotoxicity. |
| Decitabine | LOW | Both Atorvastatin and Decitabine can increase the risk of hepatotoxicity. |
| Demeclocycline | LOW | Both Atorvastatin and Demeclocycline can increase the risk of hepatotoxicity. |
| Doxycycline | LOW | Both Atorvastatin and Doxycycline can increase the risk of hepatotoxicity. |
| Eravacycline | LOW | Both Atorvastatin and Eravacycline can increase the risk of hepatotoxicity. |
| Fludarabine | LOW | Both Atorvastatin and Fludarabine can increase the risk of hepatotoxicity. |
| Fluorouracil | LOW | Both Atorvastatin and Fluorouracil can increase the risk of hepatotoxicity. |
| Flutamide | LOW | Both Atorvastatin and Flutamide can increase the risk of hepatotoxicity. |
| Gemcitabine | LOW | Both Atorvastatin and Gemcitabine can increase the risk of hepatotoxicity. |
| Heparin | LOW | Both Atorvastatin and Heparin can increase the risk of hepatotoxicity. |
| Isoniazid | LOW | Both Atorvastatin and Isoniazid can increase the risk of hepatotoxicity. |
| Isotretinoin | LOW | Both Atorvastatin and Isotretinoin can increase the risk of hepatotoxicity. |
| Lenalidomide | LOW | Both Atorvastatin and Lenalidomide can increase the risk of hepatotoxicity. |
| Lymecycline | LOW | Both Atorvastatin and Lymecycline can increase the risk of hepatotoxicity. |
| Mercaptopurine | LOW | Both Atorvastatin and Mercaptopurine can increase the risk of hepatotoxicity. |
| Methotrexate | LOW | Both Atorvastatin and Methotrexate can increase the risk of hepatotoxicity. |
| Micafungin | LOW | Both Atorvastatin and Micafungin can increase the risk of hepatotoxicity. |
| Minocycline | LOW | Both Atorvastatin and Minocycline can increase the risk of hepatotoxicity. |
| Nelarabine | LOW | Both Atorvastatin and Nelarabine can increase the risk of hepatotoxicity. |
| Neratinib | LOW | Both Atorvastatin and Neratinib can increase the risk of hepatotoxicity. |
| Oxandrolone | LOW | Both Atorvastatin and Oxandrolone can increase the risk of hepatotoxicity. |
| Oxymetholone | LOW | Both Atorvastatin and Oxymetholone can increase the risk of hepatotoxicity. |
| Oxytetracycline | LOW | Both Atorvastatin and Oxytetracycline can increase the risk of hepatotoxicity. |
| Paracetamol | LOW | Both Atorvastatin and Paracetamol can increase the risk of hepatotoxicity. |
| Pegaspargase | LOW | Both Atorvastatin and Pegaspargase can increase the risk of hepatotoxicity. |
| Pemetrexed | LOW | Both Atorvastatin and Pemetrexed can increase the risk of hepatotoxicity. |
| Pomalidomide | LOW | Both Atorvastatin and Pomalidomide can increase the risk of hepatotoxicity. |
| Pyrazinamide | LOW | Both Atorvastatin and Pyrazinamide can increase the risk of hepatotoxicity. |
| Streptozocin | LOW | Both Atorvastatin and Streptozocin can increase the risk of hepatotoxicity. |
| Testosterone | LOW | Both Atorvastatin and Testosterone can increase the risk of hepatotoxicity. |
| Tetracycline | LOW | Both Atorvastatin and Tetracycline can increase the risk of hepatotoxicity. |
| Thalidomide | LOW | Both Atorvastatin and Thalidomide can increase the risk of hepatotoxicity. |
| Tigecycline | LOW | Both Atorvastatin and Tigecycline can increase the risk of hepatotoxicity. |
| Tioguanine | LOW | Both Atorvastatin and Tioguanine can increase the risk of hepatotoxicity. |
| Trabectedin | LOW | Both Atorvastatin and Trabectedin can increase the risk of hepatotoxicity. |
| Valproate | LOW | Both Atorvastatin and Valproate can increase the risk of hepatotoxicity. |
| Vitamin A | LOW | Both Atorvastatin and Vitamin A can increase the risk of hepatotoxicity. |
| Vorasidenib | LOW | Both Atorvastatin and Vorasidenib can increase the risk of hepatotoxicity. |
| Zidovudine | LOW | Both Atorvastatin and Zidovudine can increase the risk of hepatotoxicity. |
| Ivosidenib | UNKNOWN | Ivosidenib is predicted to increase the exposure to Atorvastatin. Manufacturer advises use with c... |
Check Atorvastatin against your patient's full medication list
InteractRx checks all drug combinations at once — built for GP surgery pharmacists.
Use the Free Checker